Elicera Therapeutics

The patent protects Elicera's oncolytic viruses engineered to induce immunogenic cell death of cancer cells, T and NK cell activation and DC maturation, therefore having improved anticancer effect also against solid tumors. It gives Elicera exclusive rights in Japan to develop and sell treatments based on ELC-201 for cancer treatment.

"This first Notice of Allowance for ELC-201, issued by the Japan Patent Office, is an important step in building out global protection for the candidate, following our recent patent success with ELC-401 in US. It underscores the breadth and durability of our iTANK-based pipeline, signals the strength of Elicera's innovation, and gives us a stronger foundation from which to advance ELC-201", says Elicera's CEO, Johan Liwing.